Diabetes: Page 7


  • A bright yellow sign against a blue roof says "Best Buy" in bold black letters.
    Image attribution tooltip
    Daphne Howland/MedTech Dive
    Image attribution tooltip

    Best Buy to sell continuous glucose monitoring systems

    It’s the tech retailer’s first foray into prescription-based medical device sales.

    By Rebecca Pifer • Oct. 9, 2023
  • Professional photo of Wayde McMillan
    Image attribution tooltip
    Permission granted by Insulet
    Image attribution tooltip

    Insulet CFO leaves for 3M health spinoff

    Wayde McMillan is the second high-profile medtech executive in recent months to join 3M.

    By Oct. 4, 2023
  • Boston Scientific's Farapulse pulsed field ablation device. Explore the Trendline
    Image attribution tooltip
    Permission granted by Boston Scientific
    Image attribution tooltip
    Trendline

    New medical devices are reshaping the medtech industry

    From pulsed field ablation devices to glucose sensors and surgical robotics, new medical technologies are transforming patient care and how people manage their health.

    By MedTech Dive staff
  • A grey reader shows a blood glucose reading, next to a white circular device
    Image attribution tooltip
    Permission granted by Abbott
    Image attribution tooltip

    Abbott data suggests GLP-1 drugs a ‘modest accelerator’ for CGMs: analysts

    The analysis of U.S. insurance claims found people on GLP-1 therapy wear their FreeStyle Libre sensors more.

    By Sept. 29, 2023
  • A photo of a sign showing the Food and Drug Administration logo
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Intarcia’s diabetes drug-device combo voted down again by FDA panel

    The 19-member advisory committee unanimously voted against Intarcia in the review, citing cardiovascular and kidney safety concerns.

    By Gwendolyn Wu • Sept. 25, 2023
  • A white, rectangular sticker device is in front of a blue, pen-shaped device.
    Image attribution tooltip
    Courtesy of Medtronic
    Image attribution tooltip

    Medtronic receives CE mark for CGM sensor, boosting challenge to Abbott and Dexcom

    Medtronic has made the sensor smaller and eliminated the need for fingersticks to calibrate the device, bringing a challenger to market leaders Abbott and Dexcom. 

    By Sept. 25, 2023
  • Professional photo of Jeffrey Brewer
    Image attribution tooltip
    Permission granted by Bigfoot Biomedical
    Image attribution tooltip
    Q&A

    Bigfoot CEO talks Abbott acquisition, future of diabetes tech

    Jeffrey Brewer hopes to see more integrated solutions for people with diabetes, starting with the company’s partnership with Abbott.

    By Sept. 15, 2023
  • A person holds a rectangular device connected to tubing.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Insulin pump-makers grapple with questions about GLP-1s

    The new class of weight loss drugs has caused a stock selloff, but is unlikely to “meaningfully change the long-term outlook for diabetes,” analysts wrote.

    By Sept. 14, 2023
  • Exterior of FDA headquarters
    Image attribution tooltip
    Courtesy of U.S. Food and Drug Administration
    Image attribution tooltip

    FDA proposes 3 guidances to improve 510(k) clearance process

    The agency has made recommendations for selecting predicate devices, using clinical data and conducting performance testing for implants.

    By Sept. 7, 2023
  • White and black pen caps read "120 mg/dl" and a smartphone app says "Glucose in range."
    Image attribution tooltip
    Permission granted by Bigfoot Biomedical
    Image attribution tooltip

    Abbott to buy smart insulin pen cap maker Bigfoot

    The planned acquisition could shift patients interested in smart pens to Abbott’s Libre CGMs, an analyst wrote.

    By Sept. 6, 2023
  • A phone app shows a chart  with current glucose levels, next to a pen-shaped device.
    Image attribution tooltip
    Courtesy of Medtronic
    Image attribution tooltip

    Medtronic sued for allegedly sharing ‘treasure trove’ of diabetes patient data with Google

    The plaintiff said disclosures to Google are “particularly problematic” because his use of Gmail meant his personal information was “automatically linked to his real identity.”

    By Sept. 5, 2023
  • A black, square device with tubing connected to a patch is next to a phone that says "Beta Bionics" and another patch that says DexcomG6
    Image attribution tooltip
    Courtesy of Beta Bionics
    Image attribution tooltip

    Beta Bionics raises $100M to challenge Medtronic, Tandem for automated insulin dosing market

    The company’s iLet Bionic Pancreas automates insulin dosing without requiring mealtime carb counting. 

    By Sept. 1, 2023
  • A person speaks in front of a screen showing four cards that read: Lingo Glucose, Lingo Ketone, Lingo Lactate and Lingo Alcohol
    Image attribution tooltip
    Ethan Miller via Getty Images
    Image attribution tooltip
    Deep Dive

    Why medtech firms are putting diabetes tech in consumer devices

    As Abbott develops a line of wearable wellness devices, and Dexcom makes a CGM for people with diabetes who don’t take insulin, both companies are turning to new users for future growth.

    By Updated Aug. 31, 2023
  • Medtronic raises earnings forecast amid supply chain, diabetes business improvements

    The company also shared an update on the planned divestment of its monitoring and respiratory interventions segments.

    By Aug. 22, 2023
  • A smartphone on the left shows time in range, and a small, square device on the right is compared to a quarter in size.
    Image attribution tooltip
    Courtesy of Tandem
    Image attribution tooltip

    Tandem’s chief commercial officer to resign ahead of insulin pump rollout

    Brian Hansen is stepping down as Tandem prepares to roll out its new Mobi pump.

    By Aug. 21, 2023
  • Nick Jonas poses in front of a glowing background, wearing a small, round device on his upper arm
    Image attribution tooltip
    Courtesy of Dexcom
    Image attribution tooltip
    Deep Dive

    Dexcom, Abbott ramp up DTC marketing amid fight for share of growing diabetes market

    As insurers cover continuous glucose monitors for more people, device-makers are taking a page from the pharma marketing playbook.

    By Aug. 17, 2023
  • A phone-like device shows a bolus insulin measurement, with a white, U-shaped device to the right.
    Image attribution tooltip
    Courtesy of Insulet Corp.
    Image attribution tooltip

    Insulet claims EOFlow copied patch-pump design in patent suit

    Insulet filed the lawsuit as competitor Medtronic plans to buy EOFlow for $738 million.

    By Aug. 15, 2023
  • A cylindrical device on the left with a wifi signal, next to a black rounded device and a smartphone showing a blood glucose reading.
    Image attribution tooltip
    Permission granted by Senseonics
    Image attribution tooltip

    Senseonics seeks iCGM designation for implantable glucose monitor

    The company also plans to submit results of a pivotal trial for a version of its device that can be worn for a year.

    By Aug. 11, 2023
  • An injection pen containing the drug semaglutide lies on a white plate.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Device volumes to hold up against threat of Wegovy, other GLP-1 drugs: analysts

    Issues such as “nontrivial side effects, cost concerns and patient persistence” will mean physicians continue to use medical devices, analysts say.

    By Aug. 9, 2023
  • The Dexcom G7 Continuous Glucose Monitoring (CGM) System
    Image attribution tooltip
    Courtesy of Dexcom
    Image attribution tooltip

    Dexcom hails CGM share gains as driver of 25% revenue growth in Q2

    International market share gains and expanding coverage in the U.S. led the CGM maker to raise its revenue forecast for 2023.

    By July 28, 2023
  • Professional photo of Felix Lee
    Image attribution tooltip
    Permission granted by Sanofi
    Image attribution tooltip
    Q&A

    Sanofi’s Felix Lee talks DarioHealth partnership, future of digital health

    The pharmaceutical company struck a strategic agreement with digital health company DarioHealth last year aimed at helping patients with diabetes manage their blood sugar levels. 

    By July 21, 2023
  • Aveir leadless pacemaker by Abbott
    Image attribution tooltip
    Courtesy of Abbott
    Image attribution tooltip

    Abbott Q2 net profit falls as weaker COVID test sales drag on revenue

    Stronger medical device sales and a recovery in the infant formula business partly offset the impact of reduced COVID-19 testing.

    By July 20, 2023
  • A smartphone on the left shows time in range, and a small, square device on the right is compared to a quarter in size.
    Image attribution tooltip
    Courtesy of Tandem
    Image attribution tooltip

    Tandem’s Mobi insulin pump could reaccelerate growth next year: analyst

    The device, which is smaller than Tandem’s past pumps, could drive more people to switch from insulin injections, an analyst with Craig-Hallum said.

    By July 12, 2023
  • From left to right: a white cylindrical device with a cord, a smartphone app showing blood glucose levels, a square device showing a blood glucose reading, and a white circular device.
    Image attribution tooltip
    Permission granted by Medtronic
    Image attribution tooltip

    Medtronic secures Medicare coverage for MiniMed 780G insulin pump

    Medtronic has begun processing orders and will start shipping devices over the next few weeks.

    By July 10, 2023
  • Becton Dickinson logo
    Image attribution tooltip
    Permission granted by Becton Dickinson
    Image attribution tooltip

    BD to shed 60 jobs as COVID demand, diabetes spinoff affect manufacturing plant

    The cuts are the latest in a wave of workforce reductions by medtech companies including Abbott Laboratories, Cook Medical, Illumina and Thermo Fisher Scientific.

    By July 7, 2023
  • The Dexcom G7 Continuous Glucose Monitoring (CGM) System
    Image attribution tooltip
    Courtesy of Dexcom
    Image attribution tooltip
    Q&A

    Q&A: Dexcom’s Lawver shares strategy behind CGM for non-insulin users

    The continuous glucose monitor in development for people with Type 2 diabetes who don’t take insulin could expand the CGM market to 25 million more people in the U.S., the company’s new chief commercial officer said.

    By June 30, 2023